Diverse Pharmacology, Diverse Potential for Ulcerative Necrobiosis Lipoidica
PCS499 Targets NL
Our most advanced product candidate, PCS499, is an oral tablet and deuterated analog of a major metabolite of pentoxifylline (PTX or Trental®). PCS499 and its active metabolites have a diverse pharmacology profile and can act on multiple targets that play vital roles in the treatment of various conditions.
In particular, Necrobiosis Lipoidica (NL) has been selected as the lead indication for PCS499. NL is a chronic, disfiguring condition that affects the skin and subdermal tissue on the lower extremities of patients, such as the legs. Currently, there are no FDA-approved treatments for NL.
Developing effective treatments for this condition is difficult due to the various pathophysiological changes that contribute to the degeneration of tissue of NL lesions. However, PCS499 may provide a novel treatment solution for NL thanks to its metabolites, which affect many of the biological pathways that contribute to the physiological processes associated with NL.
In March 2018, we acquired exclusive rights from Concert Pharmaceuticals, Inc. to license, sublicense, develop, manufacture, use, and commercialize PCS499 worldwide.